Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

肥大型心筋症(HCM)治療薬の世界市場2017-2021

◆タイトル:Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021
◆商品コード:IRTNTR12425
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年4月5日
◆ページ数:70
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、肥大型心筋症(HCM)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、肥大型心筋症(HCM)治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

ABSTRACTAbout Hypertrophic Cardiomyopathy Therapeutics

HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.

Technavio’s analysts forecast the global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hypertrophic cardiomyopathy therapeutics market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• Merck
• Pfizer
• Sanofi

[Other prominent vendors]
• Gilead Sciences
• Novartis
• Teva Pharmaceutical Industries

[Market driver]
• Adoption of sedentary lifestyle.
• For a full, detailed list, view our report

[Market challenge]
• Technological advances in devices.
• For a full, detailed list, view our report

[Market trend]
• Development of translational bioinformatics (TBI).
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Disease overview

PART 06: Key clinical trials

PART 07: Market dynamics

PART 08: Market landscape
• Market overview
• Five forces analysis

PART 09: Market segmentation by drug-class
• Global calcium channel blockers market
• Global beta-adrenergic blockers market
• Global antiarrhythmic market
• Global anticoagulants market

PART 10: Geographical segmentation
• HCM therapeutics market in Americas
• HCM therapeutics market in EMEA
• HCM therapeutics market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges
• Market drivers
• Market challenges
• Impact of drivers and challenges on key customer segments (hospitals and pharmacies)

PART 13: Market trends
• Increasing availability of genetic tests
• Development of TBI
• Advent of genomic medicine

PART 14: Vendor landscape
• Competitive landscape

PART 15: Key vendor analysis
• AstraZeneca
• Merck
• Pfizer
• Sanofi
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

[List of Exhibits]

Exhibit 01: Types of HCM
Exhibit 02: Treatment for HCM
Exhibit 03: Snapshot of HCM therapeutics pipeline 2016
Exhibit 04: Pipeline analysis for HCM therapeutics market
Exhibit 05: Mutation
Exhibit 06: Identification of pathogenicity in genes by genetic testing
Exhibit 07: Global HCM therapeutics market snapshot
Exhibit 08: Global HCM therapeutics market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis in global HCM therapeutics market
Exhibit 10: Five forces analysis
Exhibit 11: Market segmentation based on drug class
Exhibit 12: Global calcium channel blockers market 2016-2021 ($ millions)
Exhibit 13: Global beta-adrenergic blockers market 2016-2021 ($ millions)
Exhibit 14: Global antiarrhythmic market 2016-2021 ($ millions)
Exhibit 15: Global anticoagulants market 2016-2021 ($ millions)
Exhibit 16: Global HCM therapeutics market by geography 2016 and 2021
Exhibit 17: Global HCM therapeutics market by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: HCM therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: HCM therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: HCM therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 24: Prevalence of obesity among US adults 2015
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Group of HCM individuals based on genetic tests
Exhibit 27: Competitive structure analysis of global HCM therapeutics market 2016
Exhibit 28: AstraZeneca: Key highlights
Exhibit 29: AstraZeneca: Strength assessment
Exhibit 30: AstraZeneca: Strategy assessment
Exhibit 31: AstraZeneca: Opportunity assessment
Exhibit 32: Merck: Key highlights
Exhibit 33: Merck: Strength assessment
Exhibit 34: Merck: Strategy assessment
Exhibit 35: Merck: Opportunity assessment
Exhibit 36: Pfizer: Key highlights
Exhibit 37: Pfizer: Strength assessment
Exhibit 38: Pfizer: Strategy assessment
Exhibit 39: Pfizer: Opportunity assessment
Exhibit 40: Sanofi: Key highlights
Exhibit 41: Sanofi: Strength assessment
Exhibit 42: Sanofi: Strategy assessment
Exhibit 43: Sanofi: Opportunity assessment



【資料のキーワード】

肥大型心筋症、肥大型心筋症治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[肥大型心筋症(HCM)治療薬の世界市場2017-2021] (Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021 / IRTNTR12425)販売に関する免責事項
[肥大型心筋症(HCM)治療薬の世界市場2017-2021] (Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021 / IRTNTR12425)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆